Personalis Inc
NASDAQ:PSNL
Intrinsic Value
Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. [ Read More ]
The intrinsic value of one PSNL stock under the Base Case scenario is 5.36 USD. Compared to the current market price of 1.25 USD, Personalis Inc is Undervalued by 77%.
Valuation Backtest
Personalis Inc
Run backtest to discover the historical profit from buying and selling PSNL stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Personalis Inc
Current Assets | 146.7m |
Cash & Short-Term Investments | 114.2m |
Receivables | 17.7m |
Other Current Assets | 14.8m |
Non-Current Assets | 78.4m |
PP&E | 75.2m |
Other Non-Current Assets | 3.1m |
Current Liabilities | 47.2m |
Accounts Payable | 14.9m |
Accrued Liabilities | 21.4m |
Other Current Liabilities | 10.9m |
Non-Current Liabilities | 48.4m |
Long-Term Debt | 1.2m |
Other Non-Current Liabilities | 47.2m |
Earnings Waterfall
Personalis Inc
Revenue
|
73.5m
USD
|
Cost of Revenue
|
-55.3m
USD
|
Gross Profit
|
18.2m
USD
|
Operating Expenses
|
-114.5m
USD
|
Operating Income
|
-96.3m
USD
|
Other Expenses
|
-12m
USD
|
Net Income
|
-108.3m
USD
|
Free Cash Flow Analysis
Personalis Inc
PSNL Profitability Score
Profitability Due Diligence
Personalis Inc's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
Score
Personalis Inc's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
PSNL Solvency Score
Solvency Due Diligence
Personalis Inc's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Score
Personalis Inc's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PSNL Price Targets Summary
Personalis Inc
According to Wall Street analysts, the average 1-year price target for PSNL is 4.85 USD with a low forecast of 3.54 USD and a high forecast of 7.88 USD.
Ownership
PSNL Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
PSNL Price
Personalis Inc
Average Annual Return | 3.07% |
Standard Deviation of Annual Returns | 144.33% |
Max Drawdown | -98% |
Market Capitalization | 63.1m USD |
Shares Outstanding | 50 503 900 |
Percentage of Shares Shorted | 2.96% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company is headquartered in Menlo Park, California and currently employs 325 full-time employees. The company went IPO on 2019-06-20. The firm is focused on the development of therapies by providing molecular data about each patient's cancer and immune response. The company provides sequencing and data analysis services to support the development of cancer therapies. Its NeXT Platform, which provides its biopharmaceutical customers with information on over 20,000 human genes, together with the immune system, in contrast to many cancer panels that cover over 50 to 500 genes. Its NeXT Platform is designed to provide analysis of both a tumor and its immune microenvironment from a single limited tissue sample. Its platform covers the deoxyribonucleic acid sequence of all of the approximately 20,000 human genes. The company also reports on transcriptome of a tumor, which encompasses ribonucleic acid expression across human genes, allowing it to determine which of the genomic mutations might actually be driving tumor progression.
Contact
IPO
Employees
Officers
The intrinsic value of one PSNL stock under the Base Case scenario is 5.36 USD.
Compared to the current market price of 1.25 USD, Personalis Inc is Undervalued by 77%.